Tylenol safety 'signal' fails the date test - the surfaced FDA artefact is 2021, not 2026
The Opportunity
The actionable content here is the veto itself: upstream due diligence surfaced a regulator artefact, but it is clearly dated April 2021 and does not support a fresh 2026 Tylenol escalation. That is why 7A assigns FADE and routes this to AVOID: the downside in trading these clusters is getting pulled into recycled recall content that looks scary in a headline but has no incremental information. The correct edge is avoiding the false positive.
The Timing
Mixed 55 regime and crosswind 60 makes recycled risk headlines especially dangerous because the tape can overreact before dates are checked. Freshness is 20/100 and staleness is explicitly flagged upstream as confirmed old story. The only thing that changes this is a new, 2026-dated FDA safety communication explicitly naming Tylenol with current lot/NDC details; absent that, this remains a hard AVOID.
The Evidence
The primary artefact cited upstream is the FDA recall notice at fda.gov , which is explicitly dated 2021. That date mismatch is the entire evidentiary point and is why the staleness veto is applied in 7A.